Semaglutide - GLP-1R Ligand - Sterile

Synthetic peptide analog - CAS #910463-68-2

ABOUT

Selective GLP-1R agonist – CAS #910463-68-2

Semaglutide is a long-acting and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist that has reshaped obesity and metabolic disease research. GLP-1 is an incretin hormone that regulates glucose homeostasis by stimulating glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite. Semaglutide has been approved by the FDA for the treatment of type 2 diabetes (Ozempic®/Rybelsus®), chronic weight management (Wegovy®), as well as other metabolic diseases.

More details More details

Semaglutide, a GLP-1 analog, shares 94% sequence homology with native human GLP-1. Structural modifications confer enhanced resistance to enzymatic degradation and extend its half-life to approximately 155–184 hours, supporting its therapeutic use. 

InvivoGen Semaglutide is highly pure and guaranteed sterile, making it suitable for in vivo studies. The biological activity is validated using a colorimetric bioassay consisting of an engineered cell line HEK-Blue™ GLP-1 expressing the GLP-1R together with a CREB-inducible SEAP reporter gene (see figure).
 

Key features

  • Each lot is validated using HEK-Blue™ GLP-1 cells
  • Guaranteed sterile 
  • No ultrasonication step needed
  • Endotoxin-tested

 

Illustrations on this page were created with BioRender.com.

All products are for research use only, and not for human or veterinary use.

Binding of Semaglutide to GLP-1R
Binding of Semaglutide to GLP-1R

InvivoGen also offers:

SPECIFICATIONS

Specifications

Source
Synthetic
Synonyms
GLP-1R agonist
GLP-1 analog
10463-68-2
CAS number
910463-68-2
Molecular weight
4113.64 g/mol
Purity
≥ 95 % (UHPLC)
Solubility

1 mM (4.12 mg/ml) in water or physiological water

Formulation buffer

TRIS 50 mM

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free physiological water (provided)
Sterility

0.22 µm filtration, Sterility guaranteed

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested)

In vivo studies

Quality control

Each lot is functionally tested and validated.

Additional information

Chemical formula: C187H291N45O59
Short sequence: H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}- EFIAWLVRGRG

CONTENTS

Contents

  • Product: 
    Semaglutide
  • Cat code: 
    hlc-sema
  • Quantity: 
    1 mg
Includes:

1.5 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    • -80°C
    Stability: Resuspended product is stable for 6 months at -20°C.

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

GLP-1R signaling and metabolic regulation

Peptide hormones acting through the glucagon-like peptide-1 receptor (GLP-1R) play a central role in the regulation of glucose metabolism and energy balance [1]. In pancreatic β cells, GLP-1R activation signals primarily through G protein–mediated signaling pathways involving cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), and cAMP response element–binding protein (CREB), thereby enhancing glucose-dependent insulin secretion and supporting β-cell function. Beyond its insulinotropic effects, GLP-1R signaling also influences lipid metabolism by modulating hepatic lipid handling and adipose tissue function. Dysregulation of GLP-1R signaling contributes to impaired insulin secretion, altered lipid homeostasis, hyperglycemia, and metabolic dysfunction observed in obesity and type 2 diabetes [1].

Therapeutic relevance of Semaglutide

Exploitation of GLP-1R signaling has driven the development of GLP-1R–targeted therapies. Semaglutide represents a major advancement in this field as a long-acting and highly selective GLP-1 receptor agonist designed to improve metabolic control in individuals with obesity and type 2 diabetes [2]. As a synthetic GLP-1 analog sharing approximately 94% sequence homology with native human GLP-1, semaglutide retains the biological activity of the endogenous hormone while incorporating structural modifications that enhance resistance to enzymatic degradation and prolong systemic exposure [2]. These modifications extend semaglutide’s circulating half-life to approximately 155–184 hours, enabling sustained receptor activation and supporting convenient once-weekly dosing regimens in clinical use [2]. 

Through activation of GLP-1R signaling, semaglutide enhances glucose-dependent insulin secretion, improves glycemic control, and modulates pathways involved in appetite regulation and energy balance. In both preclinical and clinical studies, semaglutide has demonstrated robust improvements in glycemic control together with significant reductions in body weight, largely through the modulation of central appetite pathways and reduced food intake [2,3]. Semaglutide-based therapies have been approved by the US Food and Drug Administration for the treatment of type 2 diabetes (Ozempic®/Rybelsus®) and chronic weight management (Wegovy®), highlighting the major clinical impact of GLP-1R–targeted therapeutics in metabolic disease [3,4].

 

References:

1. Zheng Z et al., 2024. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther. 9:234.
2. Chao AM, et al. 2023. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 33(3):159-166. 
3. Yang XD & Yang YY, 2024. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 18:2555–2570.
4. https://www.novomedlink.com/semaglutide/medicines.html
 

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?